Download PDF
Fortschr Neurol Psychiatr 2019; 87(01): 23-30
DOI: 10.1055/a-0599-0697
Skripte der Botulinumtoxin-Akademie
© Georg Thieme Verlag KG Stuttgart · New York

Botulinumtoxin bei Blasenfunktionsstörungen

Botulinumtoxin for bladder disorders
Heinrich Schulte-Baukloh
1   Urologische Gemeinschaftspraxis Turmstraße in Berlin-Mitte/Moabit
,
Ricarda Bauer
2   LMU Klinikum der Universität, Campus Großhadern, Urologische Klinik und Poliklinik
,
Wolfgang Jost
3   Universitätsklinik Freiburg, Neurozentrum
,
Jörg Wissel
4   Vivantes Klinikum Spandau, Neurologische Rehabilitation und physikalische Therapie
,
Arndt van Ophoven
5   Marien Hospital Herne, Universitätsklinikum der Ruhr- Universität Bochum, Abteilung für Neuro-Urologie
› Author Affiliations
Further Information

Publication History

eingereicht 14 September 2017

akzeptiert 22 March 2018

Publication Date:
03 December 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die neurogene Detrusorhyperaktivität und die nicht-neurogene. sog. idiopathische überaktive Blase (engl. Overactive Bladder OAB) sind gekennzeichnet durch einen imperativen Harndrang mit oder ohne Harninkontinenz, eine deutlich erhöhte Miktionsfrequenz, und sie sind häufig begleitet von einer Nykturie. Als second-line Therapie nach Versagen einer anticholinergen Behandlung dieser Erkrankungen hat sich die OnabotulinumtoxinA Detrusorinjektion fest etabliert. Der Eingriff ist sowohl im stationären als auch im ambulanten Setting und unter Allgemein- oder Lokalanästhesie durchführbar. Nebenwirkungen betreffen hauptsächlich das Auftreten von Harnwegsinfekten sowie – insbesondere bei neurogen bedingten Funktionsstörungen – den Harnverhalt. Wenn der Neurologe Hinweise auf eine Detrusorhyperaktivität hat und bisherige medikamentöse Therapieversuche nicht zu dem gewünschten Erfolg führen, empfiehlt sich somit eine Vorstellung beim Urologen zur Frage der OnabotulinumtoxinA-Detrusorinjektion.

Dieser Artikel beschränkt sich auf die zugelassenen Indikationen der OnabotulinumtoxinA Detrusorinjektionen und fasst ihre aktuelle Datenlage zusammen.

Abstract

An overactive neurogenic detrusor and an non-neurogenic overactive bladder both exhibit symptoms such as urgency and frequency, both with and without urinary incontinence, and are often accompanied by nocturia. OnabotulinumtoxinA-Detrusorinjection has become well established as a second line therapy in cases where anticholinergic medication has failed. The procedure can be performed under general or local anesthesia, in both in- and outpatient settings. The side effects of the procedure are primarily urinary tract infections and – especially in neurogenic bladder patients – urinary retention. This article focuses on the approved indications and summarizes the current scientific data.

Schlüsselwörter

neurogene Blase - Botulinumtoxin - Inkontinenz - OAB

Key words

neurogenic bladder - incontinence - OAB - botulinum toxin
 

  • Literatur

  • 1 Abrams P, Cardozo L, Fall M. et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21 (02) : 167-78
    PubMedGoogle Scholar
  • 2 Stewart WF, Van Rooyen JB, Cundiff GW. et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336
    CrossrefPubMedGoogle Scholar
  • 3 Milsom I, Abrams P, Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-766
    CrossrefPubMedGoogle Scholar
  • 4 Irwin DE, Milsom I, Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1314
    CrossrefPubMedGoogle Scholar
  • 5 Hall SA, Curto TM, Onyenwenyi A. et al. Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. Neurourol Urodyn 2012; 31: 1149-55 .
    CrossrefPubMedGoogle Scholar
  • 6 Manack A, Motsko SP, Haag-Molkenteller C. et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011; 30: 395-401
    CrossrefPubMedGoogle Scholar
  • 7 Irwin DE, Kopp ZS, Agatep B. , et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132-8
    CrossrefPubMedGoogle Scholar
  • 8 Kurosch M, Mager R, Gust K. et al. Diagnosis of overactive bladder (OAB). Urologe A 2015; 54: 421-7
    CrossrefPubMedGoogle Scholar
  • 9 De Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50: 36-52
    CrossrefPubMedGoogle Scholar
  • 10 Gunasena KT, Nimmo AJ, Morrison JF. et al. Effects of denervation on muscarinic receptors in the rat bladder. Br J Urol 1995; 76: 291-296
    CrossrefPubMedGoogle Scholar
  • 11 De Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol 2009; 194: 91-138
    PubMedGoogle Scholar
  • 12 Höfner K. Terminology and Pathophysiology of Overactive Bladder (OAB). Aktuelle Urol 2016; 6: 468-474
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50: 57-67
    CrossrefPubMedGoogle Scholar
  • 14 EAU-Guidelines 2017 “Urinary incontinence”
    PubMed
  • 15 AWMF- Leitlinie „Diagnostik und Therapie von neurogenen Blasenstörungen“ http://www.awmf.org/uploads/tx_szleitlinien/030-121l_Neurogenen_Blasenstrungen_ 2015-06-verlaengert.pdf
    PubMed
  • 16 EAU-Guidelines 2017 „Neurogenic lower urinary tract dysfunction“
    PubMed
  • 17 Wagg A. , et al. BJU Int 2012; 110: 1767-1774
    CrossrefPubMed
  • 18 Schurch B, Stöhrer M, Kramer G. , et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164: 692-7
    CrossrefPubMedGoogle Scholar
  • 19 Fachinformation OnabotulinumtoxinA (Botox®), Allergan
    PubMed
  • 20 Denys P, Del Popolo G, Amarenco G. , et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study. Neurourol Urodyn 2017; 36 (02) : 457-462
    CrossrefPubMedGoogle Scholar
  • 21 Peyronnet B, Castel-Lacanal E, Roumiguie M. , et al. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 or 200U versus abobotulinum toxin A (Dysport®) 750U in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn 2017; 36: 734-739
    CrossrefPubMedGoogle Scholar
  • 22 Paradella AC, Musegante AF, Brites C. Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A. Braz J Infect Dis. 2016; Nov-Dec; 20 (06) : 623-626 . doi: 10.1016 / j.bjid.2016.08.012. Epub 2016 Oct 18 .
    CrossrefPubMedGoogle Scholar
  • 23 Leitner L, Sammer U, Walter M. , et al. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep. 2016; Sep 12; 6: 33197 . doi : 10.1038 / srep33197.
    PubMedGoogle Scholar
  • 24 Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005; 19: 880-2
    CrossrefPubMedGoogle Scholar
  • 25 Karsenty G, Elzayat E, Delapparent T. , et al. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007; 177: 1011-14
    CrossrefPubMedGoogle Scholar
  • 26 Davis NF, Burke JP, Redmond EJ. , et al. Trigonal versus extratrigonal botulinum toxin- A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J 2015; 26: 313-9
    CrossrefPubMedGoogle Scholar
  • 27 Rovner E, Kennelly M, Schulte-Baukloh H. , et al. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011; 30: 556-562
    CrossrefPubMedGoogle Scholar
  • 28 Apostolidis A, Dasgupta P, Denys P. et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus panel report. Eur Urol 2009; 55: 100-120
    CrossrefPubMedGoogle Scholar
  • 29 Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourol Urodyn 2016; 35: 717-23
    CrossrefPubMedGoogle Scholar
  • 30 Bauer RM, Seif C, Bschleipfer T. , et al. Arbeitskreis „Urologische Funktionsdiagnostik und Urologie der Frau“ der Akademie der Deutschen Gesellschaft für Urologie. Urologe A 2015; 54: 368-72
    CrossrefPubMedGoogle Scholar
  • 31 Cruz F, Herschorn S, Aliotta P. , et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 742-750
    CrossrefPubMedGoogle Scholar
  • 32 Kennelly M, Dmochowski R, Schulte-Baukloh H. , et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn 2017; 36: 368-375
    CrossrefPubMedGoogle Scholar
  • 33 Nitti VM, Dmochowski R, Herschorn S. , et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3 placebo-controlled trial. 2017; Feb ; 197 ( 2S ) : S216-S223 . doi: 10.1016 / j.juro.2016.10.109. Epub 2016 Dec 22 .
    PubMedGoogle Scholar
  • 34 Nitti VM, Ginsberg D, Sievert KD. , et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5- year study. J Urol 2016; 196: 791-800
    CrossrefPubMedGoogle Scholar
  • 35 Shim SR, Cho YJ, Shin IS. , et al. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol 2016; Jan ; 48 (01) : 19-30 . doi: 10.1007 / s11255-015-1153-3. Epub 2015 Nov 11
    CrossrefPubMedGoogle Scholar
  • 36 Purwar B, Khullar V. Use of botulinum toxin for chronic pelvic pain. Womens Health (Lond). 2016; Jun ; 12 (03) : 293-6 . doi : 10.2217 / whe-2016-0007. Epub 2016 Jun 10
    CrossrefPubMed
  • 37 Wang J, Wang Q, Wu Q. , et al. Intravesical botulinum toxin A injections for bladder pain syndrome / interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit 2016; 22: 3257-67
    CrossrefPubMedGoogle Scholar